Redmile Group Reduces Stake in ADC Therapeutics SA to 9.9%

Redmile Group, LLC, along with its principal Jeremy C. Green and RedCo II Master Fund, L.P., filed an amended Schedule 13G on April 6, 2026, regarding their holdings in ADC Therapeutics SA (ADCT). The filing indicates that Redmile Group and Mr. Green beneficially own 12,692,841 common shares, representing a 9.9% ownership stake. This position reflects a decrease from their previously reported 15,666,731 shares. Of the total shares, 12,681,731 are held directly by various Redmile Funds, including 10,265,297 shares held by RedCo II Master Fund. Additionally, the reported total includes 11,110 shares issuable upon the exercise of warrants, restricted by a 9.99% Beneficial Ownership Blocker. While the entities hold warrants for up to 27,743,685 shares, they cannot exercise them beyond the established ownership cap. Redmile Group, LLC serves as the investment manager for the funds, and Mr. Green disclaims beneficial ownership except for his pecuniary interest. The filing confirms the shares were not acquired for the purpose of changing or influencing control of the issuer.